Genmab — Marts 2018

[mobbyduck1]

i have been following it for a long time, they all talk about how well Dara is tolerated, with very few sideeffects. Completely different story with rev, velcade, pom, dex etc

[GeorgeBest]

Thanks mobby. I just send a request to join

[E_L]

Seattle Genetics trying a new drug targeting CD48 - https://www.myelomacrowd.org/seattle-genetics-sgn-cd48a-for-patients-with-relapsed-refractory-mm/

[E_L]

i try to do my share on twitter GB

[Bulder]

E L: Will be even nicer when they get the answer: "The question going forward is why certain patients are more likely to have expanded T-cell populations compared to others, and what factors can determine this outcome."

[E_L]

Absolutely; if they can figure that out we hit the jackpot!

[E_L]

I mean that would be really nice for patients, sorry

[transalp]

samesame.. E L

[Bulder]

Isn't that what we use to call a win-win?

[E_L]

Bloomberg finally figuring out that "Hedge Funds Are Placing Record Bets That Danish Stocks Will Fall" - https://www.bloomberg.com/news/articles/2018-03-08/short-bets-soar-against-denmark-inc-in-trend-regulator-welcomes

[Solsen]

JNJ har hævet prisen på darzalex med 4,9% i US primo marts jf Novod

[E_L]

wow... really??

[Mcjean]

592m$ is shortet in Genmab, thats nearly 5% overall correct?

[Mickey_Mouse]

Hej Mcjean, hvor har du mon tallet fra ?

[JKY_VH]

se E L´s link 11:24

[Legolas23]

Hvem køber os over 1278, så vi kan komme tilbage i bull-trend. Det må være på tide OHW tager en for holdet og kommer med på lyntoget

[Mickey_Mouse]

JKY_VH og Mcjean,

[Mickey_Mouse]

ja det så jeg godt, men hvor dælen har Bloomberg tallene fra - Finanstilsynet offentliggør jo kun shorts der overstiger 0,5% og kan da ikke forestille mig at Bloomberg har insiderviden ??

[peter12]

Såvidt jeg kan se offentliggør finanstilsynet summen af alle shorts https://www.finanstilsynet.dk/da/Lovgivning/Information-om-udvalgte-tilsynsomraader/Short-selling/Offentliggjorte-positioner . Ultimo feb 3.58% i Gen ?

[E_L]

Abstract Journal of Immunotherapy - A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma - https://www.ncbi.nlm.nih.gov/pubmed/29517616?dopt=Abstract